Centessa Pharmaceuticals PLC ADR

NASDAQ CNTA

Data sourced from

and

Download Data

Centessa Pharmaceuticals PLC ADR Operating Income Per Share for the quarter ending March 31, 2024: -0.36

Centessa Pharmaceuticals PLC ADR Operating Income Per Share is -0.36 for the quarter ending March 31, 2024, a 29.86% change year over year. Operating income per share represents the amount of operating income generated by a company per outstanding share. It is calculated by dividing the operating income by the weighted average number of basic shares outstanding. This metric provides insights into the company's profitability from its core operations on a per-share basis. It is useful for evaluating the company's operational performance and comparing it with other companies on a per-share basis.

Centessa Pharmaceuticals PLC ADR Operating Income Per Share for the quarter ending March 31, 2023 was -0.51, a 12.45% change year over year.
Centessa Pharmaceuticals PLC ADR Operating Income Per Share for the quarter ending March 31, 2022 was -0.59, a 78.90% change year over year.
Centessa Pharmaceuticals PLC ADR Operating Income Per Share for the quarter ending March 31, 2021 was -2.79.

NASDAQ: CNTA

Centessa Pharmaceuticals PLC ADR

CEO	Dr. Saurabh Saha M.D., Ph.D.
IPO Date	May 28, 2021
Location	United Kingdom
Headquarters	1 Ashley Road, Altrincham, United Kingdom, WA14 2DT
Employees	77
Sector	Healthcare
Industry	Biotechnology

Description

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Key trends